Heart, Lung and Circulation最新文献

英文中文

Thrombolytics for Myocardial Infarction, Where Progress meets Pragmatism 溶栓治疗心肌梗死，进步与实用

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.12.006

Khansa Ahmad MD , Saraschandra Vallabhajosyula MSc, MD , Vinayak Nagaraja MD

引用次数: 0

Crossroads of Bifurcation PCI: Shaping Best Practice via the ABC Registry PCI分叉的十字路口：通过ABC注册表塑造最佳实践

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.12.007

Avedis Assadour Ekmejian MSc PhD FRACP FCSANZ , Virag Kushwaha BSc PhD FRACP FCSANZ , Ravinay Bhindi MSc PhD FRACP FCSANZ FESC

引用次数: 0

Integrating Psychological Intervention into Multidisciplinary Management of Pulmonary Nodules: A Critical Need for Standardised Care 将心理干预纳入肺结节的多学科管理：标准化护理的迫切需要

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.08.031

Fumu Wang MD, Haiming Wang MD

引用次数: 0

Albumin-Bilirubin Score for Contrast-Induced Acute Kidney Injury Prediction in STEMI: Critical Limitations 白蛋白-胆红素评分用于预测STEMI患者造影剂诱导的急性肾损伤：严重局限性

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.06.1037

Artur Dziewierz MD, PhD , Michał Węgiel MD, PhD , Tomasz Rakowski MD, PhD

引用次数: 0

Corrigendum to: “Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations” [Heart Lung Circ. 32(3) (2023) 287–296.] “澳大利亚动脉粥样硬化协会关于脂蛋白的立场声明(a)：临床和实施建议”的勘误表[心肺Circ. 32(3)(2023) 287-296]。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.12.011

Natalie C. Ward PhD a, Gerald F. Watts DSc, PhD, DM b,c, Warrick Bishop MBBS d, David Colquhoun MBBS e,f, Christian Hamilton-Craig MBBS g,h, David L. Hare MBBS, DPM i, Nadarajah Kangaharan MD j, Karam M. Kostner MD, PhD k,l, Leonard Kritharides MBBS, PhD m, Richard O’Brien MBBS, PhD n, Trevor A. Mori PhD b, Paul J. Nestel MD o, Stephen J. Nicholls MBBS, PhD p, Peter J. Psaltis MBBS, PhD q, Natalie Raffoul BPharm (Hons), MHM r, Harvey D. White DSc s, David R. Sullivan MBBS t

引用次数: 0

Preventing Heart Attack and Stroke Events Through Surveillance (PHASES): Evaluation of a Health Analytics System for Primary Care 通过监测（阶段）预防心脏病发作和中风事件：初级保健健康分析系统的评估。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.05.098

Penni Russell MBBS , Ellie Paige PhD , Mark Morgan BMBCh, PhD , Alyson Ross EdD , Rosemary Korda PhD , Deborah Davies PGDipNursing , Zoltan Bourne BMed , Tony Stanton MBChB, PhD , Michael Fryer MBBS , Kim Greaves MBBS

Aim

National cardiovascular disease (CVD) risk guidelines recommend population-level screening and pharmacotherapy for high-risk individuals. There is no validated system for surveillance of up-to-date risk factor measurement and treatment. This study evaluated an existing health analytics system as a potential CVD surveillance system.

Method

In a single Primary Health Network, Primary Sense health analytics system was evaluated as a CVD surveillance system. Errors were identified and corrected. Numbers of patients within different risk groups were identified, and proportions on appropriate therapy were reported.

Results

Data transfer from general practice electronic medical record systems to Primary Sense was correct, but errors were found regarding implementation of Australian CVD guidelines. Following corrections, out of a population of 254,357 individuals, 87,487 (34%) were eligible for CVD risk assessment. Of these, 4,199 (5%) had pre-existing CVD, 5,124 (6%) were clinically determined high-risk and 42,132 (54%) had no risk score available. Of those with a risk score available, 2,285 (6%) were high-risk. 11,608 patients had prior CVD, clinically determined high-risk or a high CVD risk score and 6,710 (58%) of these were inadequately treated.

Conclusions

Health analytics systems in current use have the potential to act as surveillance systems to monitor CVD preventive care but require evaluation.

目的：国家心血管疾病（CVD）风险指南推荐对高危人群进行人群水平的筛查和药物治疗。没有有效的系统来监测最新的危险因素测量和治疗。本研究评估了现有的健康分析系统作为潜在的心血管疾病监测系统。方法：在单一初级卫生网络中，对初级感官健康分析系统作为心血管疾病监测系统进行评估。发现并纠正了错误。确定了不同风险组的患者数量，并报告了适当治疗的比例。结果：从全科电子病历系统到Primary Sense的数据传输是正确的，但在澳大利亚CVD指南的实施方面发现了错误。修正后，在254,357人的人群中，87,487人（34%）符合心血管疾病风险评估的条件。其中，4199人（5%）已有心血管疾病，5124人（6%）临床确定为高危人群，42132人（54%）无风险评分。在那些有风险评分的人中，有2285人（6%）是高危人群。11,608例患者既往患有CVD，临床确定为高风险或高CVD风险评分，其中6,710例（58%）未得到充分治疗。结论：目前使用的卫生分析系统有潜力作为监测系统来监测心血管疾病预防保健，但需要进行评估。

{"title":"Preventing Heart Attack and Stroke Events Through Surveillance (PHASES): Evaluation of a Health Analytics System for Primary Care","authors":"Penni Russell MBBS , Ellie Paige PhD , Mark Morgan BMBCh, PhD , Alyson Ross EdD , Rosemary Korda PhD , Deborah Davies PGDipNursing , Zoltan Bourne BMed , Tony Stanton MBChB, PhD , Michael Fryer MBBS , Kim Greaves MBBS","doi":"10.1016/j.hlc.2025.05.098","DOIUrl":"10.1016/j.hlc.2025.05.098","url":null,"abstract":"<div><h3>Aim</h3><div>National cardiovascular disease (CVD) risk guidelines recommend population-level screening and pharmacotherapy for high-risk individuals. There is no validated system for surveillance of up-to-date risk factor measurement and treatment. This study evaluated an existing health analytics system as a potential CVD surveillance system.</div></div><div><h3>Method</h3><div>In a single Primary Health Network, Primary Sense health analytics system was evaluated as a CVD surveillance system. Errors were identified and corrected. Numbers of patients within different risk groups were identified, and proportions on appropriate therapy were reported.</div></div><div><h3>Results</h3><div>Data transfer from general practice electronic medical record systems to Primary Sense was correct, but errors were found regarding implementation of Australian CVD guidelines. Following corrections, out of a population of 254,357 individuals, 87,487 (34%) were eligible for CVD risk assessment. Of these, 4,199 (5%) had pre-existing CVD, 5,124 (6%) were clinically determined high-risk and 42,132 (54%) had no risk score available. Of those with a risk score available, 2,285 (6%) were high-risk. 11,608 patients had prior CVD, clinically determined high-risk or a high CVD risk score and 6,710 (58%) of these were inadequately treated.</div></div><div><h3>Conclusions</h3><div>Health analytics systems in current use have the potential to act as surveillance systems to monitor CVD preventive care but require evaluation.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"35 1","pages":"Pages 96-103"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145632783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the Pressure-Volume Loop in Valvular Heart Disease 了解瓣膜性心脏病的压力-容量环路。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.05.101

Mohammad Sarraf MD , Omar Chehab MD , Vinayak Nagaraja MBBS, MBiostat, FRACP

Pressure-volume (PV) loop analysis remains the gold standard for studying cardiac physiology by offering a comprehensive analysis and quantitative assessment of the heart. The PV loop analysis uncovers the complex interplay between pressure and volume within the ventricle during each cardiac cycle and provide clinicians and researchers with invaluable insights into the efficiency and performance of the heart. By plotting ventricular pressure against ventricular volume, PV loops create a closed curve, signifying the dynamic changes occurring throughout the entire cardiac cycle. This review examines the importance of mastering the fundamentals of the PV loop and understanding valvular heart disease impacting the left heart.

通过对心脏进行全面的分析和定量评估，压力-体积（PV）环分析仍然是心脏生理学研究的金标准。PV环分析揭示了每个心脏周期中心室内压力和容积之间复杂的相互作用，为临床医生和研究人员提供了关于心脏效率和性能的宝贵见解。通过绘制心室压力与心室容积的关系，PV回路形成了一条闭合曲线，表示整个心脏周期发生的动态变化。本文综述了掌握PV环基础知识和了解影响左心的瓣膜性心脏病的重要性。

引用次数: 0

Factors Facilitating Participation of Older Adults With Chronic Lung Disease in Community-Based, Peer-Support Exercise Programs: A Metasynthesis 促进老年慢性肺病患者参与社区同伴支持运动项目的因素：一项综合研究

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.07.011

Rebekkah Middleton RN, MN(Res), PhD , Christine Metusela PhD , Patricia M. Davidson RN, PhD

Background & Aim

Community-based peer-support exercise programs are important for enhancing the quality of life for older people with chronic lung disease. Given the strong evidence base for these programs, it is important to have a strong understanding of the factors that facilitate participation and engagement from the perspective of participants. This study aimed to derive empirical evidence from qualitative studies on the facilitating factors supporting the participation of older people with chronic lung disease in community-based peer-support exercise programs.

Methods

Five online databases (Scopus, Medline, CINAHL, PsychInfo, and Web of Science) were searched post-2012. Data were analysed using Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Studies were assessed for quality and data extracted. Results were synthesised using qualitative metasynthesis techniques.

Results

A total of 12 studies met the inclusion criteria and were included in the review. Three themes were identified as facilitators that support the participation of older people with chronic lung disease in community exercise programs: 1. benefits of pulmonary rehabilitation, with subthemes of health benefits, psychosocial benefits, supportive safe environment, and sustained benefits; 2. barriers to pulmonary rehabilitation, with subthemes of access barriers and personal barriers; and 3. overcoming barriers and building resilience, with subthemes building knowledge and awareness and regaining independence.

Conclusions

The review highlights that physical and psychosocial benefits of pulmonary rehabilitation community-based exercise programs for older people with chronic lung disease are facilitators for participation. Peer support in understanding the experiences of others can help increase engagement. There is a need to construct approaches that address the social determinants of health in overcoming barriers to participation in community peer-support exercise programs. A limitation is a risk of losing the nuances of contextual and theoretical aspects of individual studies.

背景与目的：以社区为基础的同伴支持运动项目对提高老年慢性肺病患者的生活质量非常重要。鉴于这些项目有强有力的证据基础，从参与者的角度对促进参与和参与的因素有一个深刻的理解是很重要的。本研究旨在从定性研究中获得支持慢性肺病老年人参与社区同伴支持运动项目的促进因素的经验证据。方法：检索2012年后的Scopus、Medline、CINAHL、PsychInfo和Web of Science 5大数据库。使用系统评价和元分析指南的首选报告项目对数据进行分析。评估了研究的质量和提取的数据。结果采用定性合成技术合成。结果：共有12项研究符合纳入标准并被纳入本综述。三个主题被确定为支持患有慢性肺病的老年人参与社区锻炼计划的促进因素：1。肺康复的益处，分主题为健康益处、社会心理益处、支持性安全环境和持续益处；2. 肺部康复障碍，分主题为获取障碍和个人障碍；和3。克服障碍，建立复原力，分主题是建立知识和意识，重获独立。结论：该综述强调，肺康复社区运动项目对慢性肺病老年人的身体和心理社会益处是促进参与的因素。在理解他人经历方面的同伴支持有助于提高参与度。有必要建立解决健康的社会决定因素的方法，以克服参与社区同伴支持运动项目的障碍。限制是一种失去个体研究的背景和理论方面的细微差别的风险。

{"title":"Factors Facilitating Participation of Older Adults With Chronic Lung Disease in Community-Based, Peer-Support Exercise Programs: A Metasynthesis","authors":"Rebekkah Middleton RN, MN(Res), PhD , Christine Metusela PhD , Patricia M. Davidson RN, PhD","doi":"10.1016/j.hlc.2025.07.011","DOIUrl":"10.1016/j.hlc.2025.07.011","url":null,"abstract":"<div><h3>Background & Aim</h3><div>Community-based peer-support exercise programs are important for enhancing the quality of life for older people with chronic lung disease. Given the strong evidence base for these programs, it is important to have a strong understanding of the factors that facilitate participation and engagement from the perspective of participants. This study aimed to derive empirical evidence from qualitative studies on the facilitating factors supporting the participation of older people with chronic lung disease in community-based peer-support exercise programs.</div></div><div><h3>Methods</h3><div>Five online databases (Scopus, Medline, CINAHL, PsychInfo, and Web of Science) were searched post-2012. Data were analysed using Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Studies were assessed for quality and data extracted. Results were synthesised using qualitative metasynthesis techniques.</div></div><div><h3>Results</h3><div>A total of 12 studies met the inclusion criteria and were included in the review. Three themes were identified as facilitators that support the participation of older people with chronic lung disease in community exercise programs: 1. benefits of pulmonary rehabilitation, with subthemes of health benefits, psychosocial benefits, supportive safe environment, and sustained benefits; 2. barriers to pulmonary rehabilitation, with subthemes of access barriers and personal barriers; and 3. overcoming barriers and building resilience, with subthemes building knowledge and awareness and regaining independence.</div></div><div><h3>Conclusions</h3><div>The review highlights that physical and psychosocial benefits of pulmonary rehabilitation community-based exercise programs for older people with chronic lung disease are facilitators for participation. Peer support in understanding the experiences of others can help increase engagement. There is a need to construct approaches that address the social determinants of health in overcoming barriers to participation in community peer-support exercise programs. A limitation is a risk of losing the nuances of contextual and theoretical aspects of individual studies.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"35 1","pages":"Pages 45-61"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stepwise Approach to Ventricular Tachycardia Ablation in Structural Heart Disease 结构性心脏病室性心动过速消融的逐步方法。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.07.013

Juan Mundisugih MBBS , Ashwin Bhaskaran MBBS, MSc , Kaimin Huang MBBS , Kasun De Silva MBBS , Samual Turnbull BSc , Tai Chung So MBBS , Kenji Hashimoto MD, PhD , Anunay Gupta MD, DM , Richard G. Bennett BSc, MBChB, PhD , Yasuhito Kotake MD, PhD , Max Bickley BSc , Timothy Campbell BSc, PhD , Saurabh Kumar MBBS, PhD

Catheter ablation has emerged as a pivotal therapeutic strategy for managing scar-related ventricular tachycardia (VT) in patients with structural heart disease (SHD). However, VT ablation can be complex and challenging because of the nature of VT circuit configurations and their interplay with the underlying SHD. This review outlines our systematic approach to VT ablation within the context of SHD, focusing on preprocedural assessment, procedural techniques, and postprocedural care. By adopting a systematic approach and leveraging technological advancements, successful VT ablation outcomes can be achieved in patients with SHD.

导管消融已成为治疗结构性心脏病（SHD）患者瘢痕相关性室性心动过速（VT）的关键治疗策略。然而，由于VT电路结构的性质及其与潜在SHD的相互作用，VT消融可能是复杂和具有挑战性的。这篇综述概述了我们在SHD背景下对室速消融的系统方法，重点是术前评估、手术技术和术后护理。通过采用系统的方法和利用技术的进步，可以在SHD患者中获得成功的VT消融结果。

引用次数: 0

Corrigendum to: “Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia” [Heart Lung Circ. 32(7), (2023) 790–797.] “儿茶酚胺能多态性室性心动过速的基因治疗”[心肺杂志32(7),(2023)790-797]的更正。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2026-01-01 DOI: 10.1016/j.hlc.2025.12.010

Paloma Remior Pérez MD a,b, Robyn J. Hylind MS, CGC a, Thomas M. Roston MD, PhD a,c, Vassilios J. Bezzerides MD, PhD a,1,∗∗, Dominic J. Abrams MBBS, MD, MBA a,1,∗

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Heart, Lung and Circulation

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀